Systemic lupus erythematosus: still a challenge for physicians.

Area of Science:

• Immunology
• Rheumatology
• Genetics

Background:

• Systemic lupus erythematosus (SLE) presents complex clinical features with diverse immune system defects.
• Early cardiovascular disease is a significant factor in SLE prognosis, alongside major organ involvement.
• Recent discoveries have elucidated mechanisms underlying SLE, including apoptotic cell handling and type I interferon pathways.

Purpose of the Study:

• To summarize recent advancements in understanding SLE pathogenesis.
• To highlight the roles of type I interferon and B lymphocyte stimulator (BLyS) in SLE.
• To discuss the implications of new genetic and environmental findings for SLE treatment.

Main Methods:

• Review of recent scientific literature on SLE.
• Analysis of genetic associations with SLE organ manifestations.
• Examination of emerging therapeutic strategies for SLE.

Main Results:

• Defects in apoptotic cell clearance, increased type I interferon gene expression, and autoreactive B cell activation are central to SLE.
• Genetic factors (e.g., STAT4, IRF8) and environmental triggers contribute to SLE.
• The development of targeted therapies, such as BLyS inhibitor belimumab, represents a significant therapeutic advance.

Conclusions:

• Increased understanding of SLE mechanisms has driven the development of novel treatments.
• Targeting key pathways like BLyS offers promising therapeutic avenues for SLE patients.
• Ongoing research continues to identify genetic and environmental factors influencing SLE and its manifestations.